"Global market size of organoids is expected to hit ~ US$ 38 Million in 2020. The demand for organoids is projected to grow at a significant CAGR of ~ 17 % between 2020-2029."
Organoids technology has seen incremental adoption in a wide range of verticals in the field of medical research to study the pathophysiology of diverse, complex human diseases. In recent years, with the alarming increase in the prevalence and incidence of genetic diseases, especially cancer, leading stakeholders have adopted strategies to develop tumor-representing cancer organoids and make them commercially available to researchers.
The scope of biopharmaceuticals is also growing with the increasing incidence of several viruses or bacteria transmitted infections or diseases. The field of monoclonal antibody therapy is that by offering the most competitive and promising drug pipelines on the biopharmaceuticals market. In 2018, the scientific community described the development of organoids as one of the greatest scientific achievements in recent times. This is not surprising because understanding real-world organ movements help scientists to study various abnormal and healthy activities in cells and to test new medications for solutions to problems such as Alzheimer's disease that have yet to be fully understood.
Recently, progress has been made in the area of 3D-cell culture and organic science. In addition, the entire pharmaceutical market has faced single-digit growth, poor supplies, and competition from the generics industry in recent years, but the biopharmaceuticals segment has become a rapidly growing sector of the industry. More than 200 biopharmaceutical products are being marketed and many more are in the process of development. Technological advancement is focused on developments in the field of 3D-cell culture and organoid analysis. The creation of organ-specific organoid models and the acceptance of biopharmaceuticals together are expected to generate high sales revenue for the organoid market during the forecast period.
Increased Demand for Biopharmaceutical Preclinical Drug Testing.
Biopharmaceutical preclinical drug testing is expected to hold maximum share (XX%) of the organoids market. Biopharmaceuticals are restorative medicines developed by the use of biotechnology, i.e. remedial or medicinal substances produced by the genetic manipulation of living cells or organisms. The variety of biopharmaceuticals is also growing with the increasing incidence of several viruses or bacteria borne infections or diseases. The field of monoclonal antibody therapy is that by offering the most competitive and promising drug pipelines on the biopharmaceuticals market. Gradually, most vaccine manufacturing processes may require the use of single-cell type strains and cultures. Recently, the advancement of 3D-cell culture and organoid research. In addition, the entire pharmaceutical industry has faced single-digit growth, weak pipelines and competition from the generics industry in recent years, but the biopharmaceuticals segment has become a rapidly growing sector of the industry. More than 200 biopharmaceutical drugs are being sold and many more are in the process of development. Technological advancement is focused on developments in the field of 3D-cell culture and organoid science. The creation of organ-specific organoid models and the acceptance of biopharmaceuticals together are expected to generate high sales revenue for the organoid market during the forecast period.
The Increase in Chronic Diseases, Including Most Forms of Cancer, and Recent little-understood Major Diseases such as Alzheimer's Have Caused Many Alarm Bells in the Healthcare Sector.
In fact, the cost of treatment for many of these diseases remains extremely high and out of reach for many patients. The growing influx of elderly people, increased investment in chronic disease research and a rising emphasis on the healthcare system are expected to drive more money into research and innovation. In addition, advancements in organoids, replacing conventional 2D cells with a 3D model, promise new growth opportunities for researchers in return. Growing concerns about systematic care options for individuals
The organoid market in Europe is anticipated to see significant growth due to rising research activities and growing government initiatives and funding.
On the basis of regional analysis, the market for organoids is divided into five major regions, including North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. The organoid market in Europe is expected to see significant growth due to rising research activities and growth initiatives and government funding to support them. Furthermore, technological advances in the medical field are estimated to expand the market in European countries such as Germany and the United Kingdom. The demand in North America is expected to see a lucrative rise in the coming years as a result of increased spending by various organizations in the healthcare sector.
Developed countries in both North America and Europe have been the top revenue sources for organoid stakeholders and are likely to remain the same in the coming years. Apart from spending on research and development, government policies and consumer awareness of animal experiments and testing have triggered the development of 3D cell culture and organoids as an alternative to vivisection, particularly in the United States.
The Organoids industry report will provide a comparative analysis of key players, including Hubrecht Organoid Technology (HUB), Cellesce Ltd., DefiniGEN, STEMCELL Technologies Inc., Qgel and OcellO B.V. The report will also provide a detailed overview of their positioning in relation to their strengths and weaknesses. The main players on the market are increasingly engaging in collaboration and mergers to find new opportunities for growth and innovation.
By Product Type:
- Intestinal Organoid
- Hepatic Organoid.
- Pancreatic Organoid.
- Colorectal Organoid.
- Neural Organoid
- Biomedical Research and Drug Discovery
- Regenerative Medicine
- Cancer Research
- Therapeutic Tools
By End User:
- Biopharmaceutical Companies
- Contract Research Organizations
- Academics and Research Institutes
- North America
- Latin America
- South Asia
- East Asia
- Middle East And Africa